The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
详细信息 查看全文
- 作者：Yukiharu Hiyoshi ; Naoya Yoshida ; Masayuki Watanabe…
- 刊名：World Journal of Surgery
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：41
- 期：2
- 页码：480-486
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Surgery; Abdominal Surgery; Cardiac Surgery; General Surgery; Thoracic Surgery; Vascular Surgery;
- 出版者：Springer International Publishing
- ISSN：1432-2323
- 卷排序：41
文摘
BackgroundDocetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC). Although the efficacy and safety of DCF have been reported, the markers that predict the patient’s response are still unknown. The aim of this study was to identify the predictive markers for a response to NAC with DCF in patients with ESCC.